We also analyzed the expression of EGFR across other cancers using the TIMER database (Figure 3), and the analysis revealed that this gene was statistically significant in 11 cancers, namely breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), GBM, head and neck squamous cell carcinoma (HNSC), kidney renal cell carcinoma (KIRC), kidney renal cell papillary cell carcinoma (KIRP), lung squamous cell carcinoma (LUSC), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), and uterine corpus endometrial carcinoma (UCEC). Here, EGFR is linked to pheochromocytoma-paraganglioma.